Dr. Michael D. Prados, MD

PNOC Co-Founder, Co‑Project Leader

Dr. Michael D. Prados is a neuro-oncologist whose career at UCSF spans more than four decades, encompassing the care of both adults and children with brain tumors, as well as leadership in translational and early-phase clinical trials. He was the Project Leader of the Adult Brain Tumor Consortium and Ivy Consortium, as well as UCSF Project lead of the Pediatric Brain Tumor Consortium. He co-founded the Pediatric Neuro-Oncology Consortium (PNOC) and co-leads its project portfolio, and was scientific co-chair of the Children’s Brain Tumor Network (CBTN). Dr. Prados has published over 400+ papers advancing therapy development and precision neuro-oncology. He previously held the Charles B. Wilson, MD, Endowed Chair in Neurological Surgery and has served as President of the Society for Neuro‑Oncology (SNO).

Education

Education

  • BS, University of New Orleans, LA

  • MD, LSU Health New Orleans, LA

  • Internship, Internal Medicine, Charity Hospital (Medical Center of Louisiana at New Orleans)

  • Residency, Internal Medicine, Earl K. Long Medical Center / LSU

  • Medical Oncology Training, Earl K. Long Medical Center/LSU

  • Fellowship, Pulmonary Disease, Tulane University School of Medicine

  • Fellowship, Neuro‑Oncology, UCSF

Certifications

Certifications

  • American Board of Internal Medicine, Internal Medicine (1977)

Awards

Awards & Recognition

  • Victor Levin Award for lifetime excellence in clinical research, Society for Neuro‑Oncology (2014)

  • President, Society for Neuro‑Oncology (2004–2006); Vice President (1995–1997)

  • Clinical Excellence Award, Society for Neuro‑Oncology (1997)

  • Scientific Executive Co‑Chair, Children’s Brain Tumor Network (CBTN) (former)

Research & Publications

Selected Research & Clinical Publications

  • Mueller S, Kline C, Lu AY, Hoogendijk R, Wembacher‑Schroeder E, Banerjee A, Reddy AT, Raber S, Hoffman C, Stoller S, Prados M, Molinaro A, Gupta N. PNOC009: Convection‑enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro‑Oncol Adv. 2025;7(1):vdaf093. doi:10.1093/noajnl/vdaf093.

  • Prados MD. Current Strategies for Management of Medulloblastoma. Diagnostics (Basel). 2023;13(16):2622. doi:10.3390/diagnostics13162622.

  • Margol AS, Molinaro AM, Onar-Thomas A, Resnick A, Hanson D, Kieran M, Mishra-Kalyani P, Rivera D, Barone A, Arons D, Meehan C, Prados M. Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials. J Clin Oncol. 2024 Apr 20;42(12):1340-1343. doi: 10.1200/JCO.23.01084. Epub 2024 Feb 23. PMID: 38394473

  • Yankelevich M, Zaky W, Lafay-Cousin L, Osorio D,  Adamski J, Kordes U, Finlay JL, Prados M, Mueller S. Marrow-ablative Consolidation Chemotherapy and Molecular Targeted Therapy Delivered in a Risk-adapted Manner for Newly Diagnosed Children with Choroid Plexus Carcinoma: A Work in Progress, Neuro-Oncology Advances, 2024; vdae109, https://doi.org/10.1093/noajnl/vdae109

For a complete list of published work:

http://www.ncbi.nlm.nih.gov/pubmed/?term=Michael+Prados